Skip to content
ClinCalc Pro
Menu
Amphetamine prodrug stimulant

Lisdexamfetamine mesilate

Brand names: Elvanse

Lisdexamfetamine mesilate is a long-acting prodrug stimulant (converted to dexamfetamine) used for attention deficit hyperactivity disorder, typically as part of a comprehensive treatment programme.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

After absorption it is metabolised to active dexamfetamine, which increases synaptic dopamine and noradrenaline by promoting release and blocking reuptake, improving attention and reducing impulsivity.

Prescribing in practice

  • As a stimulant it can raise heart rate and blood pressure and is contraindicated in significant cardiovascular disease, so assess cardiovascular history and check blood pressure, heart rate and growth before and during treatment.
  • It is a controlled drug with potential for dependence and misuse and should not be used where there is a history of stimulant or substance misuse without specialist judgement.
  • Monitor for psychiatric effects such as new or worsening anxiety, agitation, tics or psychotic symptoms, and for appetite suppression and growth retardation in children.

Monitoring

Monitor heart rate, blood pressure, weight, height and appetite, mental state and for signs of dependence throughout treatment.

Counselling the patient

  • Take in the morning to avoid disturbed sleep.
  • Report chest pain, palpitations, fainting or new mood or behavioural changes.
  • Reduced appetite is common; keep regular meals and attend growth and monitoring checks.

Evidence & guidelines

NICE ADHD guidance includes lisdexamfetamine among recommended stimulant options, with structured cardiovascular and growth monitoring.

Reference: NICE NG87; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.